Praxis Precision Medicines (NASDAQ:PRAX) Stock Acquired Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently bought shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX). In a filing disclosed on September 04th, the Representative disclosed that they had bought between $1,001 and $15,000 in Praxis Precision Medicines stock on July 30th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Mesabi Trust (NYSE:MSB) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Alkermes (NASDAQ:ALKS) on 7/30/2026.
• Sold $15,001 – $50,000 in shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) on 7/30/2026.
• Sold $100,001 – $250,000 in shares of Alibaba Group (NYSE:BABA) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Adobe (NASDAQ:ADBE) on 7/24/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of SailPoint (NASDAQ:SAIL) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Glacier Bancorp (NYSE:GBCI) on 7/21/2026.
• Sold $1,001 – $15,000 in shares of FedEx (NYSE:FDX) on 7/21/2026.
• Purchased $1,001 – $15,000 in shares of Marvell Technology (NASDAQ:MRVL) on 7/17/2026.

Praxis Precision Medicines Stock Performance

NASDAQ:PRAX traded down $0.65 during trading hours on Tuesday, reaching $351.17. The company’s stock had a trading volume of 68,330 shares, compared to its average volume of 459,440. The firm has a market capitalization of $9.80 billion, a price-to-earnings ratio of -27.21 and a beta of 2.76. The firm has a 50-day simple moving average of $338.95 and a 200-day simple moving average of $323.32. Praxis Precision Medicines, Inc. has a 1 year low of $37.24 and a 1 year high of $392.70.

Praxis Precision Medicines (NASDAQ:PRAX) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($2.87) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.67) by $0.80. Equities analysts anticipate that Praxis Precision Medicines, Inc. will post -13.92 earnings per share for the current fiscal year.

Analysts Set New Price Targets

PRAX has been the topic of a number of analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $650.00 price target (down from $750.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Wedbush cut their target price on shares of Praxis Precision Medicines from $166.00 to $162.00 and set an “underperform” rating on the stock in a report on Tuesday, June 2nd. Raymond James Financial reissued a “strong-buy” rating and issued a $945.00 price target on shares of Praxis Precision Medicines in a report on Monday, August 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $575.00 price target (up from $470.00) on shares of Praxis Precision Medicines in a research note on Friday, August 21st. Finally, BTIG Research reissued a “buy” rating and set a $810.00 price objective on shares of Praxis Precision Medicines in a research report on Wednesday, July 29th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $585.95.

Insiders Place Their Bets

In related news, Director Jill Desimone sold 11,600 shares of the firm’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $311.32, for a total transaction of $3,611,312.00. Following the completion of the transaction, the director owned 2,337 shares of the company’s stock, valued at $727,554.84. This trade represents a 83.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Praxis Precision Medicines

Institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC grew its position in shares of Praxis Precision Medicines by 3,000.0% in the 1st quarter. Parallel Advisors LLC now owns 124 shares of the company’s stock worth $40,000 after buying an additional 120 shares during the period. Danske Bank A S purchased a new stake in Praxis Precision Medicines in the fourth quarter worth about $59,000. GAMMA Investing LLC increased its stake in shares of Praxis Precision Medicines by 10.3% during the second quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock valued at $111,000 after purchasing an additional 31 shares in the last quarter. ABS Direct Equity Fund LLC purchased a new position in shares of Praxis Precision Medicines during the first quarter valued at approximately $135,000. Finally, Los Angeles Capital Management LLC purchased a new stake in shares of Praxis Precision Medicines in the 4th quarter worth approximately $163,000. Institutional investors own 67.84% of the company’s stock.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Praxis Precision Medicines Company Profile

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.